Pressmeddelanden från ALK-Abello

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors 20 feb 14:55

Annual General Meeting in ALK-Abelló A/S on 16 March 2026 20 feb 07:32

Henriette Mersebach to step down as ALK’s head of R&D 20 feb 07:18

Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin 13 feb 12:16

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026 29 jan 16:15

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children 08 jan 17:17

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco 22 dec 2025 16:13

ALK – Financial calendar for the 2026 financial year 19 dec 2025 22:47

Major shareholder announcement 01 dec 2025 15:35

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America 12 nov 2025 17:22

Nine-month interim report (Q3) 2025 (unaudited)12 nov 2025 17:16

ALK upgrades its full-year outlook 06 nov 2025 17:02

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025 17 sep 2025 09:44

ALK and GenSci partner to expand the AIT market in China 08 sep 2025 14:22

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray 04 sep 2025 12:31

ALK expands the Executive Leadership Team to include key commercial regions 21 aug 2025 07:30

Six-month interim report (Q2) 2025 (unaudited)14 aug 2025 14:57

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025 12 aug 2025 14:45

ALK upgrades its full-year revenue outlook 21 jul 2025 12:25

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system 18 jul 2025 14:01

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK 26 jun 2025 09:17

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany 16 jun 2025 14:03

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 04 jun 2025 16:48

ALK participates at Jefferies Global Healthcare Conference 2025 in New York 08 maj 2025 16:28

ITULATEK® approved for treatment of children and adolescents in Canada 06 maj 2025 07:30

Three-month interim report (Q1) 2025 (unaudited)02 maj 2025 13:59

ALK enters into neffy® co-promotion agreement in the USA 29 apr 2025 16:39

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025 23 apr 2025 15:58

ITULAZAX® tree pollen tablet approved for treatment of children in Europe 03 apr 2025 16:24

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees 13 mar 2025 18:06

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025 07 mar 2025 14:34

ACARIZAX® approved in Canada for treatment of young children 04 mar 2025 22:20

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff 27 feb 2025 21:51

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children 21 feb 2025 15:59

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff 19 feb 2025 14:46

Annual General Meeting in ALK-Abelló A/S on 13 March 2025 19 feb 2025 07:32

Annual report 2024: ALK delivers 15% sales growth with profits up 65%12 feb 2025 17:02

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025 30 jan 2025 10:13

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system 20 dec 2024 17:09

ALK – Financial calendar for the 2025 financial year 18 dec 2024 12:51

Positive results advance peanut tablet to phase II development 12 dec 2024 16:06

ACARIZAX® approved in Europe for treatment of young children 27 nov 2024 13:45

ALK’s pivotal phase 3 trial in children published in reputable scientific journal 14 nov 2024 07:30

Nine-month interim report (Q3) 2024 (unaudited)09 nov 2024 23:30

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)07 nov 2024 12:09

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024 27 aug 2024 17:30

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff 22 aug 2024 17:49

Six-month interim report (Q2) 2024 22 aug 2024 17:38

ALK upgrades its full-year revenue and earnings outlook 14 aug 2024 11:58

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024 21 jun 2024 18:43

ALK upgrades its full-year revenue and earnings outlook 21 jun 2024 18:38

ALK provides update on regulatory process for the house dust mite allergy tablet in China 03 jun 2024 18:02

ALK launches new growth strategy and 2028 financial ambitions 03 jun 2024 07:00

ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies 30 maj 2024 13:44

ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review 29 maj 2024 10:56

Listen in on ALK’s Capital Markets Day on 4 June 2024 02 maj 2024 19:43

Three-month interim report (Q1) 2024 (unaudited) 02 maj 2024 19:26

ALK upgrades its full-year revenue outlook 24 apr 2024 16:35

Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024 03 apr 2024 15:40

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees 26 mar 2024 14:00

Save the date for ALK’s Capital Markets Day on 4 June 2024 14 mar 2024 17:40

Annual General Meeting in ALK-Abelló A/S held on 14 March 2024 05 mar 2024 16:45

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff 04 mar 2024 16:00

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff 16 feb 2024 14:00

Annual General Meeting in ALK-Abelló A/S on 14 March 2024 12 feb 2024 16:15

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff 12 feb 2024 11:30

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff 08 feb 2024 13:35

Annual report 2023: ALK delivers 9% sales growth with profits up 50%07 feb 2024 20:10

ALK and McMaster researchers discover new cell that remembers allergies 05 feb 2024 09:30

ALK’s 2030 CO2 reduction targets have been approved by SBTi 31 jan 2024 09:44

Release date of annual report 2023 for ALK and webcast 25 jan 2024 13:15

ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review 18 jan 2024 15:34

ALK completes first part of phase 1 trial with peanut SLIT-tablet 04 jan 2024 14:00

ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy 20 dec 2023 10:45

ALK – Financial calendar for the 2024 financial year 12 dec 2023 16:08

ALK expands partnership with Torii in Japan 15 nov 2023 07:30

Nine-month interim report (Q3) 2023 09 nov 2023 13:46

Release date of nine-month interim report (Q3) 2023 for ALK and audio cast 11 okt 2023 16:13

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children 24 aug 2023 07:30

Six-month interim report (Q2) 2023 18 aug 2023 12:45

Release date of six-month interim report (Q2) 2023 for ALK and audio cast 19 jun 2023 08:40

President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor 08 jun 2023 16:27

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children 09 maj 2023 07:20

Three-month interim report (Q1) 2023 01 maj 2023 10:18

Release date of three-month interim report (Q1) 2023 for ALK and audio cast 17 apr 2023 18:15

ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook 31 mar 2023 17:30

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees 23 mar 2023 17:17

Annual General Meeting in ALK-Abelló A/S held on 23 March 2023 02 mar 2023 17:14

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff 27 feb 2023 10:00

Annual General Meeting in ALK on 23 March 2023 10 feb 2023 08:30

ALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO)08 feb 2023 17:04

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff 03 feb 2023 12:48

Regulatory filing for house dust mite allergy tablet accepted for review in China 03 feb 2023 12:08

Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022 27 jan 2023 14:12

Release date of annual report 2022 for ALK and audio cast 21 dec 2022 08:34

Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK 19 dec 2022 17:33

ALK – Financial calendar for the 2023 financial year 30 nov 2022 17:24

Management change at ALK 10 nov 2022 07:30

Nine-month interim report (Q3) 2022 03 nov 2022 14:15

Release date of nine-month interim report (Q3) 2022 for ALK and audio cast